Intriguingly, CEBPACT mutations have recently been reported to sensitize AML to treatment with hypomethylating agents by disrupting the inhibitory interaction with DNMT3A mediated by the wild-type CEBPA bZIP domain69. This evidence concerns the gene DNMT3A and acute myeloid leukemia.